Stock Analiz

Gilead Sciences, Inc. (GILD) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Gilead Sciences’s revenue went from $30.4B in fiscal 2016 to $29.4B in fiscal 2025, a decline of about 0.4% a year.

Net income in fiscal 2025 was $8.5B, a net margin of 28.9%; the best year in this period was 2016 with $13.5B.

Over the twelve months to September 30, 2026, revenue was $31.0B and net income -$3.9B.

Free cash flow was $9.5B in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count fell 8% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $30.4B162017: $26.1B172018: $22.1B182019: $22.4B192020: $24.7B202021: $27.3B212022: $27.3B222023: $27.1B232024: $28.8B242025: $29.4B25$29.4B
Net income
2016: $13.5B162017: $4.6B172018: $5.5B182019: $5.4B192020: $123M202021: $6.2B212022: $4.6B222023: $5.7B232024: $480M242025: $8.5B25$8.5B
Free cash flow
2016: $16.3B162017: $11.3B172018: $7.5B182019: $8.3B192020: $7.5B202021: $10.8B212022: $8.3B222023: $7.4B232024: $10.3B242025: $9.5B25$9.5B
EPS (diluted)
2016: $9.94162017: $3.51172018: $4.17182019: $4.22192020: $0.10202021: $4.93212022: $3.64222023: $4.50232024: $0.38242025: $6.7825$6.78

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$31.0B$29.4B$28.8B$27.1B$27.3B$27.3B$24.7B$22.4B$22.1B$26.1B$30.4B
Gross profit$24.8B$23.2B$22.5B$20.6B$21.6B$20.7B$20.1B$17.8B$17.3B$21.7B$26.1B
Operating income-$2.4B$10.0B$1.7B$7.6B$7.3B$9.9B$4.1B$4.3B$8.2B$14.1B$17.6B
Net income-$3.9B$8.5B$480M$5.7B$4.6B$6.2B$123M$5.4B$5.5B$4.6B$13.5B
EPS (diluted)$-3.16$6.78$0.38$4.50$3.64$4.93$0.10$4.22$4.17$3.51$9.94
R&D$6.3B$5.8B$5.9B$5.7B$5.0B$4.6B$4.9B$9.1B$5.0B$3.7B$5.1B
Revenue growth—+2.4%+6.0%−0.6%−0.1%+10.6%+10.0%+1.5%−15.2%−14.1%−6.9%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$14.5B$10.0B$10.8B$8.0B$9.1B$11.4B$8.2B$9.1B$8.4B$11.9B$17.0B
Capital spending-$699M-$563M-$523M-$585M-$728M-$579M-$650M-$825M-$924M-$590M-$748M
Free cash flow$13.8B$9.5B$10.3B$7.4B$8.3B$10.8B$7.5B$8.3B$7.5B$11.3B$16.3B
Dividends paid$4.1B$4.0B$3.9B$3.8B$3.7B$3.6B$3.4B$3.2B$3.0B$2.7B$2.5B
Buybacks$1.4B$1.9B$1.1B$1.0B$1.4B$546M$1.6B$1.7B$2.9B$954M$11.0B
Stock-based pay$913M$894M$835M$766M$637M$635M$643M$636M$845M$638M$380M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$7.6B$10.0B$7.3B$6.4B$6.5B$7.4B$24.4B$30.1B$25.5B$11.9B
Debt—$25.5B$27.3B$25.7B$25.8B$27.3B$32.1B$25.3B$27.8B$33.5B$26.3B
Equity—$22.7B$19.3B$22.8B$21.2B$21.1B$18.2B$22.5B$21.4B$20.4B$18.9B
Total assets—$59.0B$59.0B$62.1B$63.2B$68.0B$68.4B$61.6B$63.7B$70.3B$57.0B
Shares (diluted)1.25B1.25B1.25B1.26B1.26B1.26B1.26B1.28B1.31B1.32B1.36B

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin79.9%78.8%78.3%76.0%79.3%75.8%81.5%79.2%78.1%83.3%86.0%
Operating margin-7.6%34.0%5.8%28.1%26.9%36.3%16.5%19.1%37.1%54.1%58.0%
Net margin-12.5%28.9%1.7%20.9%16.8%22.8%0.5%24.0%24.6%17.7%44.4%
FCF margin44.5%32.1%35.8%27.4%30.6%39.6%30.4%37.1%33.8%43.3%53.6%
ROIC—18.1%2.5%12.8%12.2%15.4%6.4%7.1%11.7%20.7%30.8%
ROE—37.5%2.5%24.8%21.6%29.5%0.7%23.9%25.5%22.6%71.5%

Frequently asked questions

What is Gilead Sciences’s annual revenue?

$29.4B in fiscal 2025 and $31.0B over the twelve months to September 30, 2026.

How much profit does Gilead Sciences make?

Net income was $8.5B in fiscal 2025 (net margin 28.9%).

Is Gilead Sciences’s revenue growing?

Yes: revenue rose 2.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.